前列腺健康指数在未活检黑人男性中的性能
研究纳入135例无癌黑人对照和158例因PSA升高初次活检的黑人男性,评估前列腺健康指数(PHI)对Gleason分级分组2-5前列腺癌的检测效能。结果显示PHI与PSA区分度相似,但PSA≥4.0联合PHI≥28.0可安全减少17.9%不必要的活检,同时保持90.4%敏感性。
要点
- 在PSA 4.0-10.0 ng/ml的黑人男性中,PHI与PSA对GG2-5前列腺癌的区分度相似(0.63 vs 0.57,p=0.27)。
- PSA≥4.0联合PHI≥28.0可避免17.9%的活检,并维持90.4%的GG2-5癌敏感性。
- PSA≥4.0联合PHI≥35.0避免33.0%活检,但漏诊17.3%的GG2-5前列腺癌。
核心结论
- PHI在黑人男性中对Gleason分级分组2-5前列腺癌具有中等准确性。
- PHI≥28.0可安全用于避免部分不必要的活检。
研究设计与样本
- 研究纳入135例无癌黑人对照和158例因PSA升高初次活检的黑人男性。
- 比较活检队列中前列腺癌病例与对照,并评估PHI在不同区间的GG2-5癌概率。
主要发现
- 活检受试者中32.9%患有Gleason分级分组2-5前列腺癌。
- 在PSA 4.0-10.0 ng/ml的黑人男性中,PHI与PSA对GG2-5癌的区分度相似(0.63 vs 0.57,p=0.27)。
- 在PSA≤10.0的黑人男性中,PSA≥4.0阈值对GG2-5癌的敏感性为90.4%。
- PSA≥4.0联合PHI≥35.0序贯检测避免33.0%的活检,但漏诊17.3%的GG2-5癌。
- PSA≥4.0联合PHI≥28.0序贯检测避免17.9%的活检,同时维持90.4%的GG2-5癌敏感性。
关键数值与推荐
- PHI≥28.0与PSA≥4.0联合使用时,可避免17.9%的活检,GG2-5癌敏感性为90.4%。
- PHI≥35.0与PSA≥4.0联合使用时,可避免33.0%的活检,但漏诊17.3%的GG2-5癌。
临床怎么用
- 对于PSA升高的黑人男性,可考虑PSA≥4.0联合PHI≥28.0作为序贯检测,以减少不必要的活检。
- 需权衡PHI阈值提高带来的活检减少与GG2-5癌漏诊风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Prostate Health Index is validated for prostate cancer detection but has not been well validated for Gleason grade group 2-5 prostate cancer detection in Black men. We hypothesize that the Prostate Health Index has greater accuracy than prostate specific antigen for detection of Gleason grade group 2-5 prostate cancer. We estimated probability of overall and Gleason grade group 2-5 prostate cancer across previously established Prostate Health Index ranges and identified Prostate Health Index cutoffs that maximize specificity for Gleason grade group 2-5 prostate cancer with sensitivity >90%. MATERIALS AND METHODS: We recruited a "cancer-free" Black control cohort (135 patients) and a cohort of biopsy naïve Black men (158) biopsied for elevated prostate specific antigen. Descriptive statistics compared the prostate cancer cases and controls and the frequency of Gleason grade group 2-5 prostate cancer across Prostate Health Index scores. Receiver operating characteristics compared the discrimination of prostate specific antigen, Prostate Health Index and other prostate specific antigen related biomarkers. Sensitivity and specificity for Gleason grade group 2-5 prostate cancer detection were assessed at prostate specific antigen and Prostate Health Index thresholds alone and in series. RESULTS: Of biopsied subjects 32.9% had Gleason grade group 2-5 prostate cancer. In Blacks with prostate specific antigen from 4.0-10.0 ng/ml, Prostate Health Index and prostate specific antigen had similar discrimination for Gleason grade group 2-5 prostate cancer (0.63 vs 0.57, p=0.27). In Blacks with prostate specific antigen ≤10.0, a threshold of prostate specific antigen ≥4.0 had 90.4% sensitivity for Gleason grade group 2-5 prostate cancer; a threshold of prostate specific antigen ≥4.0 with Prostate Health Index ≥35.0 in series avoided unnecessary biopsy in 33.0% of men but missed 17.3% of Gleason grade group 2-5 prostate cancer. Prostate specific antigen ≥4.0 with Prostate Health Index ≥28.0 in series spared biopsy in 17.9%, while maintaining 90.4% sensitivity of Gleason grade group 2-5 prostate cancer. CONCLUSIONS: The Prostate Health Index has moderate accuracy in detecting Gleason grade group 2-5 prostate cancer in Blacks, but Prostate Health Index ≥28.0 can be safely used to avoid some unnecessary biopsies in Blacks.
引用
- Babajide R, Carbunaru S, Nettey OS, et al. Performance of Prostate Health Index in Biopsy Naïve Black Men. J Urol. 2020. PMID: 33103942. doi:10.1097/JU.0000000000001453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。